TORNTPHARM - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 4.2
| Stock Code | TORNTPHARM | Market Cap | 1,52,041 Cr. | Current Price | 4,494 ₹ | High / Low | 4,556 ₹ |
| Stock P/E | 68.1 | Book Value | 250 ₹ | Dividend Yield | 0.71 % | ROCE | 27.8 % |
| ROE | 26.2 % | Face Value | 5.00 ₹ | DMA 50 | 4,270 ₹ | DMA 200 | 3,944 ₹ |
| Chg in FII Hold | 0.05 % | Chg in DII Hold | -0.09 % | PAT Qtr | 584 Cr. | PAT Prev Qtr | 606 Cr. |
| RSI | 61.9 | MACD | 69.4 | Volume | 2,13,107 | Avg Vol 1Wk | 2,91,975 |
| Low price | 3,102 ₹ | High price | 4,556 ₹ | PEG Ratio | 2.80 | Debt to equity | 0.25 |
| 52w Index | 95.7 % | Qtr Profit Var | 20.4 % | EPS | 65.0 ₹ | Industry PE | 30.5 |
📊 Chart Analysis: TORNTPHARM trades at ₹4,494, above both its 50 DMA (₹4,270) and 200 DMA (₹3,944), signaling strong bullish momentum. RSI at 61.9 indicates mildly overbought conditions. MACD at 69.4 is positive, confirming bullish crossover. Bollinger Bands show price near the upper band, suggesting strong upward momentum with caution for short-term pullback. Current volume (2.1L) is below the 1-week average (2.9L), reflecting reduced participation despite price strength.
📈 Momentum Signals: Short-term momentum is bullish. Sustained trade above ₹4,500 could trigger further upside, while support lies near ₹4,400.
💡 Entry Zone: ₹4,350–₹4,450 (support near DMA levels).
🚪 Exit Zone: ₹4,550–₹4,600 (resistance near recent highs).
🔎 Trend Status: The stock is trending upward with strong bullish signals, though RSI suggests caution for near-term consolidation.
Positive
- 📌 EPS of ₹65.0 with consistent profitability.
- 📌 ROCE of 27.8% and ROE of 26.2% show strong efficiency.
- 📌 Low debt-to-equity ratio (0.25) indicates financial stability.
- 📌 PAT remains strong at ₹584 Cr. despite slight decline.
Limitation
- ⚠️ High P/E of 68.1 compared to industry PE (30.5), suggesting overvaluation.
- ⚠️ PEG ratio of 2.80 highlights expensive growth outlook.
- ⚠️ DII holding decreased (-0.09%), showing reduced domestic institutional support.
Company Negative News
- ❌ PAT declined slightly from ₹606 Cr. to ₹584 Cr.
- ❌ RSI nearing overbought levels, risk of short-term pullback.
Company Positive News
- ✅ FII holding increased (+0.05%), reflecting foreign investor confidence.
- ✅ Strong 52-week index performance at 95.7% shows robust price momentum.
Industry
- 🌐 Pharma sector remains resilient with strong demand and growth potential.
- 🌐 Industry PE at 30.5 is lower than TORNTPHARM’s PE, suggesting premium valuation for the company.
Conclusion
📌 TORNTPHARM is trending upward with strong bullish signals supported by MACD, RSI, and moving averages. Traders may consider entries near ₹4,350–₹4,450 and exits around ₹4,550–₹4,600. While fundamentals are solid with strong efficiency and profitability, high valuation and reduced DII interest warrant cautious optimism for medium-term investors.
For deeper clarity, we could refine support and resistance mapping, expand on volume analysis to confirm sustainability, or dive into RSI and MACD signals for short-term trading cues.